Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Genomic Health, Inc.
Genomic Health Announces Expansion of Oncotype DX Breast Cancer Test to Include Quantitative Estrogen Receptor ER and Progesterone Receptor PR Scores
June 17th, 2008
Genomic Health, Inc. (NASDAQ:GHDX) announced that the Journal of Clinical Oncology (JCO) published results of a study confirming RT-PCR by Oncotype DX can deliver quantitative gene expression levels for assessing estrogen receptor (ER) and progesterone receptor (PR) status, which are critical factors in determining the use and benefit of hormonal therapy for the treatment of breast cancer. Based on these results, Genomic Health is now providing quantitative ER and PR scores to physicians and patients in addition to the Recurrence Score(TM) result provided in the Oncotype DX(R) report. Unlike traditional methodologies that provide either a positive or negative result, or...
Source: Cancer Weekly (2008-06-17)
|
